ImmunoVaccine Technologies Inc.
$2,655,429.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- September 4, 2020 – August 31, 2022
- Reference
- nrc-cnrc:172-2020-2021-Q3-957553
Published purpose
In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-19 pandemic. We believe our targeted peptide epitope approach has the potential to optimize and exceed the safety and efficacy profile of more conventional vaccines. DPX-COVID-19 utilizes a multi-target approach, to optimize immune response against virus’ weaknesses, enhance efficacy at preventing infection and reduce potential for immune escape, even in case of a virus mutation. Fully synthetic, DPX-COVID-19 has the potential for fast and large-scale manufacturing to supply a significant number of doses rapidly compared to more conventional vaccines.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.